Shares of

LanVision Systems

(LANV)

were among the best-performing health-related stocks Tuesday, rising 25.7% after the company, which does business as Streamline Health, said that it has partnered with

IBM

(IBM) - Get Report

to develop and provide software for hospital organizations.

The company plans to use IBM's sales and support resources to expand its presence in the healthcare market, with particular emphasis on small- to medium-sized hospital organizations. "Our partnership with IBM will allow Streamline Health to expand into the small to medium-sized hospital market much faster and more effectively," the company said. Shares traded up 84 cents to $4.11.

Northfield Laboratories

( NFLD) fell 1.6% after the company posted a third-quarter loss that was wider than expected. The company posted a loss of $4.8 million, or 21 cents a share. A year ago the company posted a loss of $3.5 million, or 20 cents a share. An analyst polled by Thomson First Call had been expecting a smaller loss of 17 cents a share. At the end of February, the company had cash of more than $102 million. Shares traded down 25 cents to $15.50.

Shares of

QLT

(QLTI)

fell 2.7% after the company announced the resignation of its chief financial officer. The departure of Michael Doty is effective April 15. QLT said that Cameron Nelson, vice president of finance, would act as CFO until a permanent replacement is found. Shares of the biopharmaceutical company traded down 34 cents to $12.10.

BioSource

( BIOI) rose 3.8% after the company rejected an unsolicited bid from

Bio-Rad Laboratories

(BIO) - Get Report

to buy the company for $8.50 a share in cash. BioSource rejected the offer, which was formally made on April 6, because it believes the price is "significantly below" its inherent value. On April 6, Bio-Rad, which already owns close to 5% of BioSource's outstanding shares, said that it had made repeated attempts to pursuade BioSource to merge with it. "Each of these attempts," Bio-Rad said, "was rebuffed by the BioSource board of directors." At the time, Bio-Rad said that it wanted to complete the deal in a friendly manner but said that by delivering its proposal notice it was preserving its ability to pursue a proxy solicitation. Shares of BioSource traded up 36 cents to $9.91, well above the $8.50 offer price, suggesting that BioSource investors are holding out for a much higher price. Shares of Bio-Rad Labs traded down 3 cents to $50.05.

Other health care movers included

Pfizer

(PFE) - Get Report

, up 42 cents to $26.88;

Aastrom Biosciences

(ASTM)

, up 27 cents to $2.45;

Amgen

(AMGN) - Get Report

, up $1.25 to $60.58;

Johnson & Johnson

(JNJ) - Get Report

, down 25 cents to $68.64;

Elan

(ELN)

, up 5 cents to $3.77;

StemCells

(STEM)

, up 49 cents to $3.65;

Schering-Plough

( SGP), down 22 cents to $19.30;

Merck

(MRK) - Get Report

, up 67 cents to $33.81; and

Millennium Pharmaceuticals

( MLNM), up 9 cents to $8.31.